Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases by unknown
IMPORTANCE OF GUT MICROBIOTA
According to the famous words of Hippocrates, his
statement that “all disease begins in the gut” seems to be of great
importance nowadays. With these words the father of the
modern medicine suggested the essential role played by gut and
diet in many vital homeostatic functions of the human body (1).
In the recent decade our understanding of the role of the human
gut microbiome has been revolutionized by enormous advances
in development of molecular methods (especially high
throughput DNA sequencing). Based on this knowledge, the gut
microbiome is concerned as the most densely populated and
diverse microbial communities (2). Approximately, more than
500 different microbial species constituting up to 100 trillion
(1014) microorganisms per human that can colonize the intestinal
tract making an additional acquired organ weighing ca. 1.5 – 2
kg (Fig. 1). The human gut microbiota is remarkably diverse.
The colonization of gut by microbes begins after delivery and
the baby early life environment plays a crucial role in the
development of healthy microbiome. Once fully developed, gut
microbiome becomes the essential acquired organ that provides
many vital functions to the host. Currently it has been suggested
that 4 different Phyla (Bacteroidetes, Actinobacteria, Firmicutes
and Proteobacteria) consisting of thousands of mostly anaerobic
species inhabit the human gut with a steep, stomach acid-driven
proximal-distal gradient (Fig. 1). The number of genes in
microbiota outnumber human genes by one hundredfold (3). The
general human population can be stratified on the sole basis of
three dominant bacteria (i.e. the concept of enterotypes), or
subjects categorization according to their microbiome gene
richness. Both aspects have been strengthened by recent studies
investigating the impact of nutrients (e.g., dietary fibers, fat
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In the recent decade our understanding of the role of the human gut microbiome has been revolutionized by advances
in development of molecular methods. Approximately, up to 100 trillion (1014) microorganisms per human body colonize
the intestinal tract making an additional acquired organ that provides many vital functions to the host. A healthy gut
microbiome can be defined by the presence of the various classes of microbes that enhance metabolism, resistance to
infection and inflammation, prevention against cancer and autoimmunity and that positively influence so called brain-
gut axis. Diet represents one of the most important driving forces that besides environmental and genetic factors, can
define and influence the microbial composition of the gut. Aging process due to different changes in gut physiology (i.e.
gastric hypochlorhydria, motility disorders, use of drugs, degenerative changes in enteric nervous system) has a
profound effect on the composition, diversity and functional features of gut microbiota. A perturbed aged gut
microbiome has been associated with the increasing number of gastrointestinal (e.g. Clostridium difficile infection -
CDI) and non-gastrointestinal diseases (metabolic syndrome, diabetes mellitus, fatty liver disease, atherosclerosis etc.).
Fecal microbiota transplantation (FMT) is a highly effective method in the treatment of refractory CDI. FMT is the term
used when stool is taken from a healthy individual and instilled during endoscopy (colonoscopy or enteroscopy) into a
gut of the sick person to cure certain disease. FMT represents an effective therapy in patient with recurrent CDI and the
effectiveness of FMT in the prevention of CDI recurrence had reached approx. 90%. There is also an increasing evidence
that the manipulation of gut microbiota by FMT represents a promising therapeutic method in patients with
inflammatory bowel disease and irritable bowel syndrome. There is also an increased interest in the role of FMT for the
treatment of metabolic syndrome and obesity which collectively present the greatest health challenge in the developed
world nowadays. Targeting of gut microbiota by FMT represents an exciting new frontier in the prevention and
management of gastrointestinal and non-gastrointestinal diseases that awaits further studies in preclinical and clinical
settings.
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feeding) and dietary habits (i.e., vegans versus omnivores) of
different populations (4).
From the clinical point of view the most of the microbial
species can be detected by culture independent methods such as
16s ribosomal RNA sequencing method. Importantly, each
individual has its own unique microbiota, so the gut microbiome
of each individual is like a fingerprint. The composition of the gut
microbiota remains relatively stable from late childhood to old
age, when changes occur again due to aging process (5, 6). More
recently, groups of bacterial families have been classified into
enterotypes on the basis of their functions. This classification is
based on metabolism of dietary components and ability to tolerate
and metabolize drugs which should help to further understanding
of the role of enteric microbiota in health and disease. Aging is
associated with changes in diversity of non-cultured species, with
a greater proportion of Bacteroides species, a distinct abundance
of Clostridium clusters, an increased enterobacteria population,
and a lower number of Bifidobacteria (7, 8).
The human beings lifestyle, diet and medical interventions
including pharmacological therapy including use of antibiotics
and proton pump inhibitors have profound impact on the
composition (diversity) of the gut microbiota (9). The
impairment of homeostasis by dysbiosis may increase
susceptibility to inflammatory bowel diseases (IBD) (9). The
environment, genetics, and host immunity form a highly
interactive regulatory triad that have been shown to regulate toll
like receptor (TLR) function. Imbalanced relationships within
this triad may promote aberrant TLR signaling, critically
contributing to formation of inflammasome resulting in acute
and chronic intestinal inflammatory processes, such as in IBD
consisting of Crohn disease and ulcerative colitis, and colorectal
cancer (10). In particular, IBD are characterized by idiopathic
intestinal inflammation that can arise from predisposing genetic
(genes encoding proteins relevant to both innate and adaptive
immunity: NOD2, STAT3, IL-23 receptor, etc.) and
environmental factors (specific TLRs ligands, and antigens
derived from commensal bacteria) acting on the
immunoregulatory system. It is generally accepted that IBD may
be result of an imbalance of proinflammatory- and regulatory-T-
cells responses (11, 12).
The “last human organ“ plays a central role in the
development of immune system, alterations in intestinal functions
and defense against pathogens and metabolism (13) (Fig. 2).
Beyond the microbial richness (diversity), a healthy gut
microbiome is characterized by the presence of the microbes that
enhance metabolism, resilience to infection and inflammation,
resistance to cancer and autoimmunity and the positive influence
on brain-gut axis (14, 15). Importantly, the gut microbiota affects
the intestinal mucosa via interaction with epithelial cells, enteric
nervous system leading to changes in gut motility, sensory
functions and pain perception (microbiota-brain-gut axis) (16)
(Fig. 2). Microbiota-brain interactions constitute an exciting area
of research which may contribute to the new insights into
individual predispositions in cognition, personality, mood, sleep,
and eating behavior (17). Moreover, this interaction can help in
understanding of a wide range of neuropsychiatric diseases
ranging from affective disorders to autism, depression and
schizophrenia (Fig. 2). Gut microbes affect the functions of
intestinal barrier, especially its permeability as well as cell
proliferation and production of IgA and defensins (18).
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Fig. 1. Spatial and longitudinal variations in microbial numbers and composition across the length of the gastrointestinal tract. The
human microbiota contains as many as 1014 bacterial cells, whose number that is 10 times greater than the number of human cells
present in the bodies. The number of bacterial cells present in the mammalian gut shows a continuum that goes from 102 to 103 bacteria
per gram of contents in the stomach and duodenum, progressing to 104 to 107 bacteria per gram in the jejunum and ileum and
culminating in 109 to 1012 cells per gram in the colon.
The mechanism by which microbiota may contribute to the
function of brain-gut axis remains unknown but microbes
release many biologically active substances such as enteric
short chain fatty acids (SCFA) that show strong
immunomodulatory and sensory effects. Among the SCFAs,
the acetic acid (AA), butyric acid (BA), and propionic acid
(PPA) are the most aboundant (19). The SCFAs consist of the
major class of signaling molecules produced from bacterial
fermentation of dietary carbohydrates, odd-chain fatty acids,
and some proteins (20, 21). SCFAs act as major energy
substrates and directly affect the host digestive tract through
phenotypic alteration of colonic epithelial cells. They can act
as tumor suppressor agents, in apoptotic cell death, and have
recently been shown to be modulators of the enteric
neuroendocrine system. SCFAs are also involved in gene
regulation of anti-inflammatory processes both in vitro and in
vivo (19, 22). Interstingly, SCFAs whose presence in diet has
been documented, can be also produced by opportunistic gut
bacteria following fermentation of dietary carbohydrates. They
are considered to act as environmental triggers in autism
spectrum disorders. With other words, microbes and their
metabolites regulate not only the local mucosal immune system
through both pro-inflammatory and anti-inflammatory
mechanisms but can exert a central effects in brain system (9,
23) (Fig. 2).
One of the most important factors influencing the
composition and function of the microbiota is our diet. The type
of diet may have great influence on the composition of the gut
microbiome. So it is not surprising that westernized diet that is
high in sugar and fat leads to the impairment of the gut
microbiota termed dysbiosis (24). The data in rodents have
shown that within the first week of ingestion of a high fat diet, a
significant increase in paracellular permeability in the small
intestine has been observed. These permeability changes were
accompanied by expression of IL-10 and the genera in the class
Clostridia significantly correlated with these early onset changes
(25). In contrast, transcellular flux increased in the large
intestine and at time points later than first week. These changes
correlated significantly with genera in the order Bacteriodales
and coincided with increased adiposity, body weight, and plasma
levels of lipopolysaccharide-binding protein, together with
increased expression of IL-1β in the ileum. Moreover, a positive
correlation between proinflammatory cytokine expression in the
ileum (IL-1β) and adiposity was observed. Interstingly, a
decrease in anti-inflammatory gene expression (IL-10) preceded
the increase in the proinflammatory cytokine expression. This
was corroborative with the observation that IL-10 knockout mice
have increased intestinal permeability before the onset of
microbiota-induced gut inflammation (26).
The perturbation of the gut microbiota can be initiated by a
number of extrinsic and intrinsic factors. The consequence of
this perturbations is the movement from normobiosis (healthy
gut) to dysbiosis as documented by less richness of microbiota
and its diversity, negative of both, compositional and functional
features. This impairment of gut microbiota has been associated
with the development of number of diseases in the
gastrointestinal (GI) tract and beyond GI tract (27).
According to recent advances in microbiome research, the
infectious, inflammatory and functional bowel diseases are
closely associated with the pathologic changes in gut microbiota.
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Fig. 2. Physiologic role of gut microbiota influenced by diet: the bidirectional effect of gut microbiota on the brain-gut axis, defense
against pathogens, effect on metabolism via microbiota-liver axis and alterations of intestinal functions including an impact on
intestinal permeability, sensory and motility functions.
Beyond the gut, especially the metabolic diseases and
neurological disorders due to dysfunction of brain-gut axis and
dysbiosis have been linked with the pathology within the gut as
manifested by the sensory dysfunction and intestinal
permeability thus predisposing to gastrointestinal diseases (28).
One of the important discoveries in the last years is the fact that
the disbalance of gut microbiome has a profound impact on the
function of the liver via microbiota-liver axis (Fig. 2). The
mechanisms through which microbes and their metabolites
affect the metabolic homeostasis are just at the beginning to be
understood. One of the consequences of dysbiosis is “leaky gut”
i.e. increased gut permeability and increased microbial
translocation through the mucosal barrier leading to metabolic
endotoxemia and subsequent low-grade inflammation. The
consequence of this phenomenon is the increased generation of
proinflammatory cytokines and free radicals leading to
inflammation in the liver or pancreas. In contrast, healthy
microbiota is an important factor in the prevention of metabolic
dysregulation (29).
Leaky gut and dysbiosis have been linked with the
development of non-alcoholic liver disease and nonalcoholic
steatohepatitis as well as diabetes mellitus and metabolic
syndrome (30). The member of new generation of antibiotic
designed to treat lower bowel disorders such as rifaximin exerts
a multifaceted mechanism of action that include a direct
antimicrobial effect, the inhibition of bacterial translocation
across the gut mucosal epithelium and subsequent alteration in
the release and/or absorption of endotoxin and bacterial
metabolites, and modulation of gut-immune signaling (31).
MICROBIOTA AND AGING
The relationship exist between the microbiota and a variety
of clinical problems associated with erderly, including physical
frailty, Clostridium difficile (C. difficile) colitis, vulvovaginal
atrophy, colorectal carcinoma, and atherosclerotic disease. The
stratification of the proper composition of microbiota and
microbiome of older adults holds promise to work out as an
innovative strategy against the development of comorbidities
associated with aging (32). This aging process, affecting many
aspects of gut physiology (erderly change of diet,
hypochlorhydria, use of drugs, motility disorders), has a
profound effect on the composition, diversity and functional
features of gut microbiota (Fig. 3). The main gut bacterial phyla,
in the order of numerical importance, are Firmicutes,
Bacteroidetes, Actinobacteria, Proteobacteria, Verrucomicrobia
and Fusobacteria (32). Firmicutes are gram-positive bacteria
including the large class of Clostridia and the lactic acid
bacteria, while Actinobacteria are gram-positive bacteria,
including Colinsella and Bifidobacterium spp. The lactic acid
bacteria and Bifidobacteria are two important types of gut
bacteria, which are autochthonous ones from birth or acquired
from digested food. Lactobacillus and Leuconostoc spp. are the
main lactic acid bacteria found in the human intestine.
Bifidobacterium spp. is the predominant bacteria found among
the first colonizers of newborns, and persists at a low level in
adults (34). Interestingly, in aging the number of Firmicutes
increases while the number of SCFA-producing Bacetroidetes
significantly decreases (35, 36) (Fig. 3).
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Fig. 3. Impact of aging on gut microbiota, pathology of gastrointestinal tract and various clinical consequences leading to dysbiosis
causing chronic inflammation resulting from impairment of mucosal barrier, generation of reactive oxygen metabolites (ROS),
proinflammatory mediators, the decrease in diversity of gut microbiota, increased risk of Clostridium difficile infection (CDI) and
functional gastrointestinal disorders (FGID).
Due to aging process the diversity (richness) decreases and
the propensity to develop the pathological C. difficile infection
significantly increases along with immune dysregulation
followed by the abundance of local and systemic
proinflammatory markers (IL-1β, TNF-α and CRP) (Fig. 3).
Additionally, the increasing permeability of gut barrier due to
dysbiosis may increase the risk of developing numerous chronic
diseases (37) (Fig. 3). The effect of aging process on the gut
microbiota composition is nowadays receiving a considerable
interest, especially from the perspective of improving the
wellness of aged people by modulating the gut microbiota in
elderly (38). On the other hand, the link between gut microbiota
and the aging process is only partially understood, with the gut
ecosystem exhibiting the potential to become a promising target
for strategies considered to improve the health status of aging
population (39).
FECAL MICROBIOTA THERAPY
AND C. DIFFICILE INFECTION
Based on existing evidence it is not surprising that C. difficile-
induced colitis is one of the emerging infectious diseases of the GI
tract in elderly patients. The intestinal inflammation caused by C.
difficile is characterized by diarrhea, pseudomembranous colitis
and sometimes complicated by life-threading fulminate colitis. C.
difficile colitis is a serious complication of antibiotic use and
prolonged hospitalization. Based on huge number of studies, the
impairment of microbiota and its decreased diversity appear to be
the major factors in the pathogenesis of C. difficile. Besides the
use of antibiotics, other risk factors such as increased age (> 65
years), comorbidity or use of drugs (especially proton pump
inhibitors) are responsible for the decrease of microbiota diversity
and increased predisposition to the development of this disease.
From the clinical point of view C. difficile colitis is characterized
by increasing incidence, complication and mortality rates. This
phenomenon is partly due to bacterial virulence factors and
production of bacterial toxins. This disease is associated with
increased length of hospitalization and therapy costs. C. difficile
infection shows recurrent character and the development of
recurrences increase the resistance to antibiotic therapy after each
episode of C. difficile infection (40-42).
The main problem of C. difficile infection in the clinical
practice results from its recurrent character. Despite appropriate
antibiotic treatment, some patients develop chronic recurrent C.
difficile infection. The development of recurrences increases
after each episode of C. difficile infection. A recurrent episode
of C. difficile infection may be result of incomplete eradication
of the offending strain and its spores or could reflect reinfection
with new pathogenic strain (43). The initial therapy against C.
difficile conventionally consists of antibiotics such as
metronidazole or vancomycin. Unfortunately, the antibiotic
therapy of the initial episode of C. difficile infection fails in 19
– 30% of cases. Recently, more effective novel antibiotic
fidaxomycin has been successfully introduced. After first
recurrence, fidaxomycin was more effective than vancomycin
and the cure-rate in the first group was 76% compared to 59%
in the vancomycin group. Fidaxomycin is almost non-
absorbable from GI tract and less disturbing to gut microbiota
as compared to vancomycin. Despite these advances in the
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Fig. 4. Schematic presentation of the fecal microbiota transplantation (FMT) from healthy donor (healthy gut) to a patient with
dysbiosis. The routes of FMT administration may be different (e.g. via nasojejunal tube, gastroscopy, enteroscopy or colonoscopy).
antibiotic therapy of C. difficile, the effectiveness of the
antibiotic therapy after its each refractory episode decreases
dramatically (up to 30%). In patients with multiple relapses, the
effectiveness of all antibiotic approaches including fidaxomycin
is significantly reduced and other treatment modalities are
definitely needed (44).
The majority of data indicating that healthy microbiota is
required for human health and protects against disease, have
focused so far on microbiota-induced therapeutic potential and
possible clinical interventions based on delivery of probiotic
microbiota and compounds containing probiotics. Moreover, the
fecal microbiota transplantation (FMT) has been shown to be
much more effective than antibiotics against recurrent or
refractory C. difficile colitis (45). FMT refers to the transfer of
feces obtained from the healthy donor into the patient’s
gastrointestinal tract via different routes (gastric, jejunal or
colonoscopic route) (Fig. 4). Currently, there is no consensus
which is the best delivery method for the infusion of feces. In
contrast to antibiotics, FMT is the only method that has been
reported to restore the intestinal homeostasis and prevent the
recurrence of C. difficile infection (46, 47).
The first published evidence on introducing FMT was
published by Eiseman et al. (48), but historically this method
was already known in the ancient China. Despite effectiveness of
this method, fecal material has potential risks for the recipient as
a treatment with the use of an active biological material, so this
treatment is still considered as premature in terms of mechanism
of action and the consequences that it may cause. Each donor
must be screened for infectious diseases (HIV, hepatitis, C.
difficile. etc). Besides laboratory screening, each donor is
additionally screened based on history including recent
antibiotic therapies, use of immunosuppressive drugs, exposure
to HIV or hepatitis, history of allergic, inflammatory, metabolic
or malignant disease. It is of great importance that donor of feces
should be as healthy as possible. There is a hope that FMT may
eventually prove beneficial for the treatment of other diseases
associated with alterations in gut microbiota such as IBD,
irritable bowel syndrome (IBS) and metabolic syndrome.
Although the basic principles that underlie the mechanisms by
which FMT shows therapeutic efficacy in CDI are becoming
apparent, further research is still needed to understand the
possible role of FMT in the therapy of not only CDI patients but
also other GI and non-GI disorders (49).
There are numerous routes available by which FMT can be
administered (Fig. 4). The advantage and disadvantage of each
method of application is different. The FMT via
nasogastric/nasojejunal tube is minimally invasive and
considered as a low cost procedure. The disadvantage for the
patients is the increased risk of aspiration and vomiting. The use
of gastroscopy or enteroscopy may overcome some of these
problems, but these methods are invasive, require sedation and
are associated with higher costs. The most common way to
application the FMT is colonoscopy. The main advantage of this
method is the fact that it is more appealing to patients and
probably more effective in the therapy of CDI. In addition, the
colonoscopy enables the direct evaluation of the lower tract and
exclusion of other pathologies (Fig. 4). The disadvantage of this
method are higher costs, need of sedation and risks of
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Fig. 5. The proposed mechanism of stress acting via brain-gut axis affecting the enteric nervous system (ENS) and gut microbiota that
may lead to dysbiosis, increased intestinal permeability and functional gastrointestinal disorders (FGID). The importance of probiotics,
transfer of fecal microbiota from healthy donor and modern therapy with antibiotics such as rifaximin to counteract dysbiosis and
restore the hypersensitive and pain sensory signals from the gut and alterations in motility of lower bowel. 
complications due to colonoscopy (perforations, bleeding and
others). Finally, the use of stool in a manufactured prepared
capsule from a standard screened donor represents an non-
invasive method for FMT that could minimize the obviates risk
and cost of endoscopy and donor screening. However, the
effectiveness of this type of application need to be assessed in
further prospective studies.
The effective amount of feces required for FMT is still not
standardized, but amount between 50 – 100 g seems to be
sufficient for the successful microbiota transfer. Normally, the
fresh fecal preparation is used for FMT. However, the recent
study by Satokari (50) demonstrated that the use of the frozen
fecal inoculums from a standard donor can be applied for FMT
without the loss of efficacy. Frozen feces preparation showed
similar efficacy as fresh feces in treating recurrent C. difficile.
infection (51). The first randomized trial with FMT in patients
with recurrent CDI was performed by Van Nood group that
demonstrated high effectiveness of this method in the treatment
of recurrent CDI-induced colitis (52). More important, FMT led
to the restoration of intestinal homeostasis and increased
microbial diversity (52, 53).
One of the important challenges in the practical use of FMT
is the instinctive aversion to fecal material and risk of infection.
To minimize these risks, scientist are working on synthetic stool.
The development of stool banks from safe donors could be the
other alternative (54, 55).
The side effects of FMT are low and include risk of acute
infections (biosafety), allergic reactions, potential transmission
of bacteria that increase the predisposition to chronic diseases
including IBD, IBS, colorectal cancer, diabetes mellitus type 2
or metabolic syndrome (56). The only recently published the
case of unintentional weight gain after FMT supports the
concept that microbiota may transfer metabolic phenotype (57).
Finally, the patients with IBD with the impairment of intestinal
barrier were reported to have fever or Escherichia coli-induced
bacteremia after implantation of FMT. The data on long-term
side effects of FMT is still limited. Importantly, a recently
published evidence on the treatment with FMT in immune-
compromised patients demonstrated that this method is useful
and safe in these patients (58).
FECAL MICROBIOTA THERAPY
AND INFLAMMATORY BOWEL DISEASE
Gut microbiota impairment plays a fundamental role in the
pathogenesis of IBD. The rationale and further indications for
FMT to treat IBD could be due to the fact that this disease is
characterized by the pathologic immune response to bacteria or
presence of pathologic bacteria or due to both phenomenon’s.
Numerous studies have shown that IBD is associated with loss
in the richness and diversity (dysbiosis) of the gut microbiome.
The typical dysbiotic feature is the under-representation of the
anti-inflammatory phyla Bacteroides und Firmicutes and
relative increase in pro-inflammatory proteobacteria (59). The
results of FMT in IBD patients show very promising but also
discrepant results. The recent meta-analysis by Colman et al.
(60) included eighteen studies. Overall, 45% of patients
achieved clinical remission and reduced some anti-
inflammatory drugs after FMT (60). In the recent randomized
trial (61) patients with ulcerative colitis were assigned to FMT
treatment with own feces or feces from a healthy donor
administered by nasojejunal tube. Seven out of 23 patients
(30.4%) in the donor arm versus five out of 25 patients in
placebo arm (20%) achieved remission, however, the difference
was not statistical significant. Interestingly, in all responders a
microbiotic shift in microbiota composition was observed
supporting the role of microbiota manipulation in the treatment
of IBD (61). Concerning the role of FMT in the management of
IBD, there are still many open questions concerning the FMT
therapy in IBD patients including the route of administration,
frequency of application, microbiota screening in the donor,
preparation of the donor stool, administration of antibiotics to
the FMT recipient, and many others.
FECAL MICROBIOTA THERAPY
AND FUNCTIONAL GASTROINTESTINAL DISORDERS
One of the promising therapeutic target for FMT are
functional GI disorders (FGID). Numerous studies have
revealed that these commonly diagnosed diseases such as IBS
may develop due to the dysfunction of brain-gut axis evoked by
stress leading to the alterations in the mucosal inflammatory
response, visceral pain reception, colonic motility and
alterations in behavior. There are several lines of evidence
supporting the role of gut microbiota in the pathogenesis of
FGID including the differences in intestinal microbiota
composition between healthy subjects and patients with IBS,
the development of IBS after gastroenteritis (post-infectious
IBS), the efficacy of certain antibiotics (like rifaximin) and pre-
or probiotics in IBS patients and additional evidences from
animal studies (Fig. 5). FGID are accompanied by dysbiosis
indicating that the restoration of intestinal homeostasis by FMT
could have a positive effect on the natural course of these
diseases (62, 63). All these observations indicate that the gut
microbiota represents an important therapeutic target in stress-
dependent GI dysfunctions (Fig. 5). Recent studies, including
our own demonstrated that the modulation of microbiota with
probiotics or antibiotics may ameliorate the symptoms of IBS
and intestinal inflammation in rodent model of colitis (64).
Moreover, the animal studies in germ free mice indicate that the
lack of gut microbiota may have impact on memory anxiety,
sociability and the release of neurotransmitters such as BDNF
supporting the importance of brain-microbiota axis (65, 66). It
should be stressed, however, that the number of studies with
FMT in FGID is very limited and the placebo-controlled studies
are still lacking, but the first results are quite promising and
warrant further evaluation (67).
FECAL MICROBIOTA THERAPY
AND METABOLIC DISORDERS
In addition to intestinal microbiota alterations leading to GI
diseases, the manifestations of extra GI diseases include obesity
and metabolic disorders, both associated with multiple
perturbations of gut microbiota (68). Some studies indicate that
the obesity is associated with lower microbial diversity as
manifested by the shift in intestinal microbial flora e.g. an
increase in Firmicutes and a decrease in Bacteroides. It was also
demonstrated that microbiota in obese subjects is more effective
in harvesting energy from food. The adverse role of pathogenic
microbial strains in the obesity is further supported by animal
studies because the transplantation of gut microbiota from obese
to germ-free mice led to an increase in weight gain. The another
evidence of contribution of pathogenic gut microbiota to the
development of obesity is the fact that vancomycin therapy
resulted in decreased peripheral insulin sensitivity in patients
with metabolic syndrome (69). As mentioned in this review, the
microbiota produce a wide range of metabolites (e.g. SCFA) that
may exert a profound effect on the host metabolism being the
energy source for epithelial cells and play an important
triggering role for the intestinal immune system. Finally, the
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bariatric surgeries for obesity have been shown to change the
composition of microbiome (68-70). The first preliminary pilot
study in humans demonstrated that FMT from lean to obese
subject improved the insulin resistance due to compositional
changes of gut microbiota and increased number of SCFA-
producing bacteria (71).
In summary, we conclude that change in microbial
composition (dysbiosis) can be implicated in the increasing
propensity for a broad range of gastrointestinal and non-
gastrointestinal diseases. The gut microbiota represents an
important acquired organ, executing numerous vital functions in
the metabolism, the development of immune system and the
host defense against pathogens. Based on recent evidence in
severe and complicated C. difficile infected patients, the novel
treatment FMT with or without selected use of vancomycin (72)
leads to a successful treatment of C. difficile infection possibly
due to increased gut microbiota diversity originally manifested
by a “shift” in microflora i.e. an increase in Firmicutes and a
decrease in Proteobacteriae. The FMT shows promising results
in patients with IBD but this approach still should be further
explored by basic and clinical investigators to finally confirm
the ultimate effectiveness of this method in the treatment of this
disease. Preliminary studies have indicated that the intestinal
microbiota by means of FMT could be considered as an
important “physiologic” factor in the prevention and treatment
of metabolic dysregulation, effective in improving of the insulin
resistance and metabolic syndrome. Finally, the aberrant gut
microbiota is involved in the pathogenesis of FGID, and affects
peripheral and central pathways involved in motility, immunity
and brain gut-communication. Thus, the counteracting effect
and restoration of the intestinal homeostasis by FMT holds
promise that this procedure might also be effective in treatment
of FGID.
Conflict of interests: None declared.
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